)

Supernus Pharmaceuticals (SUPN) investor relations material
Supernus Pharmaceuticals Wells Fargo 20th Annual Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Business overview and portfolio transition
Transitioning from legacy products to a new growth phase with four key CNS-focused assets, including KELRI for ADHD, ZERZUVEY for postpartum depression, GOCOVRI for Parkinson's, and the newly launched NAPCO infusion device for Parkinson's motor fluctuations.
Recent acquisition of Sage expanded the portfolio into women's health while maintaining CNS focus, with ZERZUVEY as the first and only oral treatment for postpartum depression.
Strong collaboration with Biogen and Shionogi supports product launches and market access across multiple regions.
Continued profitability during the transition, with expectations for reaccelerated top-line growth.
Product performance and market dynamics
KELRI is experiencing rapid growth, outperforming the ADHD and non-stimulant markets, with 35% of business now in adults and 80% satisfaction in this segment.
Back-to-school season is driving further momentum for KELRI, with a 26% increase in recent weeks and expectations for a strong second half.
GOCOVRI benefits from Medicare redesign, leading to higher patient retention and lower out-of-pocket costs, though offset by increased manufacturer rebates.
NAPCO launch is meeting strong demand, providing a needed alternative for advanced Parkinson's patients, with early signs of limited cannibalization of the Apoquin pen.
ZERZUVEY is showing robust sequential growth, supported by sales force expansion and ongoing physician education.
Pipeline and R&D strategy
Evaluating Sage's legacy pipeline and integrating with internal discovery programs, with a focus on rationalizing and prioritizing early-stage assets.
Lead internal pipeline asset SPN-817 is in Phase IIb for seizures, showing promising efficacy and potential cognitive benefits.
SPN-820 for depression is being repositioned for intermittent dosing after mixed Phase IIb results, with a new trial planned before year-end and data expected by 2027.
Early-stage asset SPN-443 is advancing, with a lead indication decision expected before year-end.
Next Supernus Pharmaceuticals earnings date

Next Supernus Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage